Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251757 | 0.89 | CYP4F2 (0.43) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 | |
| SCHEMBL4325284 | 0.84 | CCR2 (0.44) | CYP4F2CYP4A11CHRM1NPSR1CCR2 | |
| SCHEMBL12759874 | 0.81 | CHRM1 (0.37) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 | |
| SCHEMBL10164849 | 0.80 | CHRM1 (0.39) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 | |
| SCHEMBL23369954 | 0.79 | CHRM1 (0.38) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 | |
| SCHEMBL1502450 | 0.78 | NPSR1 (0.35) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 | |
| SCHEMBL1502391 | 0.78 | TSHR (0.37) | CYP4F2CYP4A11CHRM1CCR2ADORA2A | |
| SCHEMBL1502377 | 0.78 | CHRM1 (0.38) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 | |
| SCHEMBL30834944 | 0.78 | CYP4F2 (0.41) | CYP4F2CYP4A11CHRM1NPSR1 | |
| SCHEMBL13698866 | 0.78 | TSHR (0.43) | CYP4F2CYP4A11CHRM1NPSR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-7915252-B2 | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915252-B2 | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915252-B2 | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1797034-B1 | SULFONYL COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1581515-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1581515-B1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1797034-A1 | SULFONYL COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006017542-A1 | SULFONYL COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1581515-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050154038-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2005-07-14 | — | — | US | disclosed |
| US-6849636-B2 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2005-02-01 | — | — | US | disclosed |
| WO-2004058730-A2 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058741-A1 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040133011-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885CHRM1 624/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885CHRM1 624/4885 |
| US-20050154038-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | CYP4F2 368/4885CYP4A11 26/4885CHRM1 4027/4885 |
| US-20040133011-A1 | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | CYP4F2 341/4885CYP4A11 27/4885CHRM1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.